Freenome: Aaron Elliott

Cancer early detection company Freenome has appointed Aaron Elliott as CEO. Elliott most recently served as CEO and president of Realm IDx, overseeing its subsidiaries Ambry Genetics, Invicro, and Konica Minolta Realm-Japan. He was also CEO of Ambry Genetics from 2016 to 2021 and led the $1 billion acquisition of Ambry by Konica Minolta in 2017 (Ambry was subsequently acquired by Tempus AI in February 2025). He joined Ambry in 2008 as an R&D scientist and later became its CSO. Elliot did his PhD training in genetics at the Sidney Kimmel Cancer Center at Thomas Jefferson University and Johns Hopkins University School of Medicine, and he holds a BS in biology from Franklin & Marshall College.